SLA2 Gene: Src Like Adaptor 2
Comprehensive genomic and functional analysis of SLA2, a key adaptor protein in immune signaling and cancer.
Gene Information Card
| Symbol | SLA2 |
|---|---|
| Full Name | Src Like Adaptor 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 20q11.23 |
| NCBI Gene ID | 84174 ncbi.nlm.nih.gov/gene/84174 |
| Ensembl ID | ENSG00000101204 |
| UniProt ID | Q9H6Q3 |
| OMIM ID | 609009 |
| HGNC ID | 20244 |
| Aliases | SLAP-2, SLAP2, MGC138207 |
Description
SLA2 (Src Like Adaptor 2) encodes a member of the Src-like adaptor protein (SLAP) family. This protein functions as an adaptor in intracellular signaling pathways, particularly in T-cell receptor (TCR) and B-cell receptor (BCR) signaling, where it negatively regulates immune responses by recruiting ubiquitin ligases to activated receptors. SLA2 is implicated in hematological malignancies and solid tumors through altered expression and mutations.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Chronic Lymphocytic Leukemia (CLL) | Altered SLA2 expression may disrupt BCR signaling, contributing to leukemogenesis. | ClinVar, COSMIC |
| Breast Cancer | SLA2 mutations and copy number alterations affect cell proliferation pathways. | COSMIC |
| Lung Cancer | Somatic mutations in SLA2 are observed, potentially impacting immune evasion. | COSMIC |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Spleen | 12.5 | Medium |
| Lymph node | 10.8 | Medium |
| Bone marrow | 8.3 | Low |
| Lung | 5.1 | Low |
| Breast | 3.2 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| K-562 (leukemia) | 15.2 | High expression |
| MCF7 (breast cancer) | 4.7 | Low expression |
| A549 (lung cancer) | 6.1 | Low expression |
| HEK293 (embryonic kidney) | 2.3 | Very low expression |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| p.Arg94Trp | Missense | <0.1% | Unknown; predicted possibly damaging |
| p.Glu129* | Nonsense | <0.01 | Loss of function |
| c.456+1G>A | Splice site | <0.01 | Likely loss of function |
Mutation functional classification
Loss of Function (LOF)
Nonsense and splice site mutations in SLA2 are predicted to cause loss of function, potentially impairing negative regulation of immune signaling.
Gain of Function (GOF)
No gain-of-function mutations have been reported for SLA2.
Dominant Negative (DN)
No dominant-negative mutations have been characterized for SLA2.
View complete mutation data:
Gene Ontology (GO)
| • SH3/SH2 adaptor activity (GO:0005070) | • signal transduction (GO:0007165) |
| • cytoplasm (GO:0005737) | • plasma membrane (GO:0005886) |
| • negative regulation of signal transduction (GO:0009968) |
Pathways
• TCR signaling (Reactome: R-HSA-202403)
• BCR signaling (Reactome: R-HSA-983705)
• Immune System (Reactome: R-HSA-168256)
Protein Summary
SLA2 is a 261-amino acid adaptor protein containing an N-terminal SH3 domain and a C-terminal SH2 domain. It interacts with activated receptor tyrosine kinases and immune receptors, recruiting Cbl ubiquitin ligases to promote receptor downregulation. SLA2 is predominantly expressed in hematopoietic tissues and plays a critical role in modulating immune responses. Dysregulation of SLA2 is associated with lymphoid malignancies and solid tumors.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SLA2 Knockout HCT 116 Cell Line | EDJ-KQ74465 | Human | 84174 | Details Get a Quote |
| SLA2 Knockout A-549 Cell Line | EDJ-KQ66041 | Human | 84174 | Details Get a Quote |
| SLA2 Knockout HeLa Cell Line | EDJ-KQ57543 | Human | 84174 | Details Get a Quote |
| SLA2 Knockout HEK293 Cell Line | EDJ-KQ10007 | Human | 84174 | Details Get a Quote |